Author reply

Anosh Sivashanmugarajah^{1

2}, Jordan Fulcher^{1

2}, David Sullivan³, Marshall Elam⁴, Alicia Jenkins^{1

5}, Anthony Keech^{1

2}

Affiliations

¹ NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
² Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
³ NSW Health Pathology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁴ Department of Pharmacology, University of Tennessee, Knoxville, TN, USA.
⁵ Department of Medicine, University of Melbourne, St Vincent's Hospital, Melbourne, Victoria, Australia.

Comment

Anosh Sivashanmugarajah et al. Intern Med J. 2020 Apr.

. 2020 Apr;50(4):507-508.

doi: 10.1111/imj.14785.

Anosh Sivashanmugarajah^{1

2}, Jordan Fulcher^{1

2}, David Sullivan³, Marshall Elam⁴, Alicia Jenkins^{1

5}, Anthony Keech^{1

2}

¹ NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
² Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
³ NSW Health Pathology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁴ Department of Pharmacology, University of Tennessee, Knoxville, TN, USA.
⁵ Department of Medicine, University of Melbourne, St Vincent's Hospital, Melbourne, Victoria, Australia.

No abstract available

Comment on

Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A, Fulcher J, Sullivan D, Elam M, Jenkins A, Keech A. Sivashanmugarajah A, et al. Intern Med J. 2019 Sep;49(9):1081-1091. doi: 10.1111/imj.14429. Intern Med J. 2019. PMID: 31507054 Review.
Pharmacogenetics of statin intolerance.
Suthers G, Somogyi AA. Suthers G, et al. Intern Med J. 2020 Apr;50(4):506-507. doi: 10.1111/imj.14788. Intern Med J. 2020. PMID: 32270606 No abstract available.